At Ensoma, we develop one-time in vivo treatments that precisely engineer any or all blood and immune cells to cure diseases from within.
Location: United States
Employees: 51-200
Total raised: $258M
Founded date: 2019
Investors 7
| Date | Name | Website |
| 12.02.2021 | 5AM Ventur... | 5amventure... |
| 06.02.2022 | Takeda Ven... | takeda.com |
| - | F-Prime Ca... | fprimecapi... |
| 06.12.2025 | AJU IB Inv... | ajuib.co.k... |
| - | Catalio Ca... | cataliocap... |
| 31.01.2023 | Solasta Ve... | solasta-ve... |
| - | SymBiosis | symbiosis.... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 23.09.2025 | - | $53M | 5AM Ventur... |
| 16.05.2023 | Series B | $50M | Delos Capi... |
| 10.01.2023 | Series B | $85M | - |
| 11.02.2021 | - | $70M | - |
Mentions in press and media 11
| Date | Title | Description |
| 26.09.2025 | Ensoma Secures $53M to Accelerate In Vivo Stem Cell Gene Therapies | Ensoma has secured $53 million in a pivotal funding round. This capital infusion accelerates its groundbreaking work in one-time, in vivo stem cell therapies. A primary goal involves progressing the Phase 1/2 clinical trial for EN-374, spec... |
| 23.09.2025 | Vertical Harvest Receives Investment From Raiven Capital (Dubai) | Vertical Harvest, Inc., a Jackson, WY-based vertical farming company recently profiled by The Washington Post as leading Vertical Farming 2.0, received an investment from Raiven Capital (Dubai). The amount of the deal was not disclosed The ... |
| 23.09.2025 | Ensoma: $53 Million Secured To Advance Stem Cell Therapies And Global Clinical Impact | Ensoma, a biotechnology company focused on transforming medicine through one-time, in vivo stem cell therapies, has announced the closing of a $53 million funding round. This investment comes from a group of leading investors who have previ... |
| 23.09.2025 | Ensoma Raises $53M in Funding | Ensoma, a Boston, MA-based in vivo hematopoietic stem cell (HSC) engineering company, raised $53M in funding. Backers included Gilead (Nasdaq: GILD), which has also appointed an executive to the Ensoma board of directors as part of its inve... |
| 22.05.2025 | Ensoma Announces FDA Clearance of IND Application for First In Vivo HSC-Directed Gene Insertion Therapy | - |
| 23.04.2024 | Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform | DRESDEN, Germany & LEXINGTON, Mass.--(BUSINESS WIRE)-- Seamless Therapeutics today announced the appointments of Albert Seymour, Ph.D., as its new President and Chief Executive Officer and Adam Rosenberg as Independent Chairman of the c... |
| 16.05.2023 | Ensoma Closes $50M Series B Extension; Brings Total Round to $135M | Ensoma, a Boston, MA-based genomic medicines company developing one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system, closed an extension of its Series B financing by $50m, bringing the total size of the... |
| 10.01.2023 | Ensoma Raises $85M in Series B Funding; Acquires Twelve Bio | Ensoma, a Boston, MA-based genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system, raised $85M in Series B funding, and acquired Twelve Bio, a Copenhagen, Denmark-based ... |
| 12.02.2021 | Daily funding roundup - February 11th, 2021 | Zocdoc raised $150M; Modern Health landed $74M; Human Interest secured $55M; WireWheel picks up $20M Zocdoc: Zocdoc is a digital healthcare scheduling platform. Zocdoc has raised $150 million in fresh funding led by Francisco Partners. Read... |
| 11.02.2021 | Fred Hutch, Univ. of Washington biotech spinout Ensoma launches with $70M in funding | Dr. Hans-Peter Kiem of the Fred Hutchinson Cancer Research Center. (Fred Hutch Photo) New spinout: Boston-based biotech startup Ensoma launched Thursday and announced a $70 million Series A funding round. The company is built on technology ... |
Show more